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MS-SMART is an ongoing multicentre, multi-arm, double blind, placebo-controlled phase IIb
randomised controlled trial to establish whether putative neuroprotective drugs (fluoxetine,
riluzole,amiloride or placebo) can slow down the progression of brain volume loss in secondary
progressive multiple sclerosis (SPMS) over 96 weeks using MRI-derived Percentage Brain Volume
Change (PBVC) as the primary outcome. 360 patients have been screened so far, 328 (92%)
consented and 272 randomized (65% of the total UK cohort–440). Patients will have outcome-data
collected after 0,24,48 and 96 weeks. The trial is using a range of conventional and novel imaging
techniques to better understand neuroprotection in SPMS. Core data includes: new and enlarging T2
lesions count, persistent new T1 hypointense lesion, whole brain atrophy, grey matter volume, and
advanced imaging in 2 centres [cervical cord area change,MR spectroscopy and Magnetic Transfer
Ratio (MTR)]. Additional measures include: CSF neurofilament levels and optical coherence
tomography (OCT) to measure Retinal Nerve Fibre Layer (RNFL) thickness. This abstract describes the
ongoing status of the trial. This independent research is awarded by the Efficacy and Mechanism
Evaluation Programme (EME) and funded by the Medical Research Council (MRC) and the Multiple
Sclerosis Society (MS Society) and managed by the National Institute for Health Research (NIHR) on
behalf of the MRC-NIHR partnership.
